Economic modelling
Markov, partitioned-survival, decision-tree, and microsimulation models — built in Excel/VBA or R, with clear technical documentation and model walkthroughs.
Health Economics & Management Consulting · Hong Kong
Evidence that moves healthcare decisions forward.
Zephyr VitaLink International partners with biopharmaceutical, medical device, payer, and public-health clients to translate clinical and real-world data into defensible economic value — across access, reimbursement, and policy.
Services
A focused practice, built around the questions that decide market access.
We design and execute the analytical work that supports reimbursement, formulary, and policy decisions — combining health economics rigour with the practical needs of commercial, medical, and government affairs teams.
-
01
Health Economics & Outcomes Research
Cost-effectiveness, cost-utility, and cost-minimisation analyses built on transparent Markov, partitioned-survival, or decision-tree models — calibrated to local payer perspectives and clinical pathways.
- De novo economic model development
- Model adaptation across jurisdictions
- Independent model review and validation
-
02
Budget Impact & Affordability
Payer-ready budget impact models that quantify the financial implications of introducing a new technology across populations, settings, and time horizons — with scenario testing for uptake, mix, and pricing.
- Static and dynamic BIM frameworks
- Affordability and value-based pricing scenarios
- Payer-facing interactive tools
-
03
HTA & Reimbursement Support
End-to-end support for health technology assessment submissions — evidence synthesis, value dossiers, response strategies, and stakeholder engagement aligned to local HTA frameworks across APAC and beyond.
- Global & local value dossiers
- Evidence synthesis & ITC / NMA
- HTA query response & defence
-
04
Real-World Evidence Strategy
RWE generation plans that anticipate evidentiary gaps before they appear — from study design and data source selection to analysis, publication, and integration into ongoing value narratives.
- RWE landscaping and feasibility
- Database, registry, and chart review studies
- Evidence integration into HTA & pricing
-
05
Policy & Program Evaluation
Independent evaluation of public-health programs and reimbursement policies — quantifying clinical, economic, and equity impact for ministries, payers, hospitals, and not-for-profits.
- Program logic & outcomes framework design
- Economic & equity impact assessment
- Policy option appraisal
-
06
Value Communication
Clear, credible, audience-tuned value stories — for payers, clinicians, policymakers, and internal stakeholders — supported by visualisations, objection handling, and field-ready materials.
- Global value narratives & payer decks
- Objection handling & AMCP-style dossiers
- Interactive value visualisations
Methods & Approach
Methodological rigour, transparently applied.
Every engagement is anchored to internationally recognised standards — ISPOR Good Practices, CHEERS, PRISMA, and local HTA guidance — with documented assumptions, reproducible code, and structured uncertainty analysis.
Evidence synthesis
Systematic literature reviews, indirect treatment comparisons, and network meta-analyses — feeding directly into economic and value evidence packages.
Survival & extrapolation
Parametric survival modelling, flexible spline approaches, and external-data calibration — with structured plausibility assessment of long-term extrapolations.
Real-world data analytics
Cohort, case-control, target-trial emulation, and propensity-score approaches across claims, EMR, registry, and primary-collection data.
Uncertainty & sensitivity
Deterministic and probabilistic sensitivity analyses, value-of-information frameworks, and scenario stress-testing — communicated for decision-makers, not just modellers.
Equity & distributional analysis
Distributional cost-effectiveness analysis and equity-informed appraisal — surfacing trade-offs that aggregate ICERs can hide.
Sectors & Stakeholders
Who we work with.
Our work sits at the intersection of clinical evidence, economic value, and policy — serving the organisations that fund, deliver, and regulate care.
Biopharmaceutical & Biotech
Global, regional, and emerging companies preparing for launch, reimbursement, or lifecycle management decisions.
Medical Devices & Diagnostics
Manufacturers building economic and clinical value cases for novel devices, diagnostics, and digital health tools.
Payers & Insurers
Public and private payers seeking independent evaluation of coverage decisions, formulary design, and benefit packages.
Government & HTA Agencies
Ministries of health, HTA bodies, and public agencies designing or evaluating reimbursement and public-health programs.
Hospitals & Health Systems
Health systems and provider networks evaluating service-line economics, technology adoption, and program design.
Foundations & NGOs
Not-for-profits, foundations, and global-health organisations evaluating interventions across LMIC and APAC contexts.
Consulting Process
A structured engagement model, calibrated to your decision timeline.
-
Step 01
Discover & scope
We start by understanding the decision the work needs to support — payer, regulator, policymaker, or internal — and agree on the question, evidence base, and success criteria.
-
Step 02
Evidence & design
We map the evidence landscape, identify gaps, and design the analytical approach — model structure, data sources, comparators, and reporting outputs.
-
Step 03
Build & validate
Models, analyses, and dossiers are built against documented standards, with peer review, validation against published benchmarks, and structured uncertainty analysis.
-
Step 04
Communicate & defend
We translate results into stakeholder-ready outputs — dossiers, decks, interactive tools — and support clients through HTA review, payer engagement, and policy dialogue.
-
Step 05
Sustain & iterate
As evidence and policy evolve, we update models and narratives — keeping the value story aligned with the latest data, comparators, and decision-maker priorities.
Why Zephyr VitaLink
Senior-led, evidence-anchored, locally fluent.
Senior practitioners on every engagement
You work directly with the people who design and build the analyses — not a delegated junior team. Less translation loss, faster iteration, better evidence.
Methodologically defensible by design
Every model and analysis is built to withstand HTA review, peer critique, and internal audit — aligned with ISPOR, CHEERS, and local technical guidance.
Anchored in Hong Kong, fluent across APAC
We understand local payer structures, HTA pathways, and clinical practice patterns across Greater China and APAC — and connect them to global value strategies.
Bilingual delivery, international standards
Deliverables in English and Chinese, structured for global teams and local stakeholders — without compromising on methodological clarity.
Transparent, reproducible work products
Documented assumptions, traceable data, and reproducible code. Clients can defend the work long after the engagement closes.
Independent & conflict-aware
We disclose interests, decline conflicts, and structure engagements so that analytical integrity is never in question — especially in evaluative work.
About the Firm
A specialist consultancy for health economics and management decisions.
Zephyr VitaLink International Limited is a Hong Kong–incorporated health management consultancy. We were founded to bring senior, methodologically rigorous health economics support to clients across Asia-Pacific — particularly those navigating fragmented payer landscapes, evolving HTA frameworks, and accelerating real-world evidence requirements.
Our practice combines formal training in health economics, epidemiology, and public health with hands-on experience supporting reimbursement, policy, and program evaluation across both established and emerging markets.
- HK Hong Kong–incorporated & based
- APAC Regional coverage & local fluency
- EN / 中文 Bilingual delivery on request
Contact
Tell us about the decision your evidence needs to support.
Share a few details and we will respond within two business days to scope a short discovery conversation. All enquiries are treated as confidential.
General enquiries
krinzy@live.comBusiness development
krinzy@live.comOffice
Hong Kong SAR
By appointment